Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record■Insider buy□Insider sell◇Significant stake declared (13D)●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Aug 13, 2026Reported sale · Form 4John Kiely · $882.0KOpen the filing ↗
- Aug 13, 2026Notice of sale · Form 144JOHN KIELY · Director · $879.7KOpen the filing ↗
- Aug 12, 2026Reported sale · Form 4Jason B. Daly, EVP, Chief Legal Officer · $3.7MOpen the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year250
SEC filings on record67221 flagged findings
Reported transactions (Form 4)80since Mar 3, 2026
Corporate events (8-K)30since Jan 12, 2021
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
What the company does
Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.
Source: Wikipedia (CC BY-SA 4.0) · copied on Sep 3, 2026 · may not reflect recent changes.
Regulatory history
Topics detected in its SEC reports, with the original excerpt.
Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.
- 2026-05-07regulatory investigationrecentOpen filing ↗“…to Note 19. Commitments and Contingencies in the Company’s Annual Report on Form 10-K for a general discussion of Medicaid…”
- 2026-05-07Department of Justice inquiryrecentOpen filing ↗“…in the process to finalize a definitive settlement agreement. These deposits, which were classified as restricted cash in the…”
+1 more passage from the same document
- “…Nationwide Opioids Settlement Agreement for the three months ended March 31, 2026 was immaterial. Refer to Note 19. Commitments and…”
- 2026-02-27capital return (buybacks/dividends)recentOpen filing ↗“…agreements restrict our operations, particularly our ability to respond to changes or to take certain actions. Our credit…”
+1 more passage from the same document
- “…ability to respond to changes or to take certain actions. Our credit agreements contain a number of restrictive covenants that…”
- 2026-02-27regulatory investigationrecentOpen filing ↗“…litigation as expense in the period when incurred for products it has developed, as well as for products which are the subject of an…”
+1 more passage from the same document
- “…has entered into a tolling agreement with respect to potential criminal charges through May 15, 2026. The Company entered into a…”
- 2026-02-27Department of Justice inquiryrecentOpen filing ↗“…letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions,…”
+1 more passage from the same document
- “…controlled substances violations. Other federal and state regulatory agencies have far reaching authority. For example, the State…”
- 2026-02-27merger or acquisition eventrecentOpen filing ↗“…Limited (incorporated by reference to Exhibit 2.5 of the Company’s Annual Report on Form 10-K filed on March 1, 2022). 2. 4 Asset…”
+1 more passage from the same document
- “…5, 2022). 2.5 Agreement and Plan of Merger, dated as of November 7, 2023, by and among Amneal Pharmaceuticals, Inc. (formerly Amneal…”
Original excerpts from SEC filings, untranslated. Not advice and not a prediction.
The 25 most recent filings (of 672)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
- Sep 3, 26S-3ASR ↗Securities offering
- Aug 13, 26Form 144 ↗Notice of proposed sale
Notice of proposed sale · 2 Form 144 filingsshow all 2hide
- Aug 12, 26Form 144 ↗Notice of proposed sale
- Aug 12, 26Form 144 ↗Notice of proposed sale
- Aug 12, 26Form 4 ↗Insider transaction
- Aug 12, 26SCHEDULE 13D/A ↗Stake with intent to influence · Tushar Patel · 17.6% · event on Aug 10, 26 · amendment
- Aug 12, 26SCHEDULE 13D/A ↗Stake with intent to influence · Chirag Patel · 8.4% · event on Aug 10, 26 · amendment
- Aug 12, 26SCHEDULE 13D/A ↗Stake with intent to influence · Chintu Patel · 9.4% · event on Aug 10, 26 · amendment
- Aug 11, 26Form 144 ↗Notice of proposed sale
- Aug 10, 268-K ↗Current report · Took on a new financial obligation
- Aug 6, 2610-Q ↗Quarterly report
- Aug 3, 268-K ↗Current report · Entered a material agreement
- Jul 31, 268-K ↗Current report · Shareholder vote results
- Jul 30, 268-K ↗Current report · Results · Communication to the market
672 filings on record, the oldest from Nov 21, 17.
Listing the 25 most recent filings of the 672 on record.
42921
- Aug 10, 26Took on a new financial obligation+5 more in the same filing8-K 2.03 ↗
- Aug 3, 26Entered a material agreement8-K 1.01 ↗
- Apr 22, 26Sold unregistered shares+4 more in the same filing8-K 3.02 ↗
- Feb 3, 26Took on a new financial obligation+1 more in the same filing8-K 2.03 ↗
- Aug 1, 25Took on a new financial obligation+2 more in the same filing8-K 2.03 ↗
- Jul 21, 25A senior executive left or was appointed+3 more in the same filing8-K 5.02 ↗
- Mar 6, 25A senior executive left or was appointed8-K 5.02 ↗
- Dec 15, 23Listing notice (8-K 3.01)+2 more in the same filing8-K 3.01 ↗
- Nov 14, 23Took on a new financial obligation+2 more in the same filing8-K 2.03 ↗
- Nov 8, 23Listing notice (8-K 3.01)+8 more in the same filing8-K12B 3.01 ↗
- Oct 17, 23Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- Sep 6, 22A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
5 older filings not shown · The record reaches back to May 7, 18.
Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.
- Jul 10, 19Restructuring plan with committed costs+2 more in the same filing8-K 2.05 ↗
- May 16, 18Restructuring plan with committed costs8-K 2.05 ↗
The full record holds 4 stress filings.
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13D: stake and stated purpose
Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.
- Tushar Patel17.6%Aug 10, 26SCHEDULE 13D/A ↗
- Patel Tushar Bhikhubhai15.7%Mar 14, 25SCHEDULE 13D/A ↗
- Chintu Patel9.4%Aug 10, 26SCHEDULE 13D/A ↗
- Chirag Patel8.4%Aug 10, 26SCHEDULE 13D/A ↗
- Patel Chintu8.2%Oct 3, 25SCHEDULE 13D/A ↗
show 2 more holdershide
- Patel Chirag K.7.1%Aug 6, 25SCHEDULE 13D/A ↗
- Patel Dipan5.4%Dec 31, 25SCHEDULE 13D/A ↗2 earlier filings
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- BlackRock, Inc.7.6%Mar 31, 26SCHEDULE 13G ↗
- UBS Group AG6.9%Sep 30, 24SCHEDULE 13G ↗
- Akram Mahesh6.6%Mar 31, 25SCHEDULE 13G/A ↗
- The Vanguard Group5.0%Mar 31, 25SCHEDULE 13G ↗
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
Sale intention announced
On Aug 13, JOHN KIELY filed notice of intent to sell up to $880K. That is about 0.02% of shares outstanding.
A notice is not a sale: it may not go ahead, may happen in part, or at a different price.
After the notice, they sold $882K on Aug 13, per their Form 4. That is 100% of the shares announced so far, and the window is still open.
View notice (Form 144) ↗+3 more recent notices · 2 with a later sale
Stock compensation, tax and giftsshow the 35 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- Sep 17, 26Giftamount n/aJ KEVIN BUCHI↗
- Sep 11, 26Compensation$295KJ KEVIN BUCHI↗
- Sep 1, 26Giftamount n/aANDREW S BOYERExecutive Vice President↗
- Aug 21, 26Giftamount n/aANDREW S BOYERExecutive Vice President↗
- Aug 13, 26Giftamount n/aJohn Kiely↗
- Aug 11, 26Compensation$2.9MJ KEVIN BUCHI↗
- Aug 10, 26Compensationamount n/aTushar Bhikhubhai Patel↗
- Aug 10, 26Compensationamount n/aChirag K. PatelPresident & Co-CEO↗
- Aug 10, 26Compensationamount n/aGautam Patel↗
- Aug 10, 26Compensationamount n/aChintu PatelCo-CEO↗
- May 7, 26Compensationamount n/aShlomo Yanai↗
- May 7, 26Compensationamount n/aPAUL M MEISTER↗
- May 7, 26Compensationamount n/aTed C Nark↗
- May 7, 26Compensationamount n/aJohn Kiely↗
- May 7, 26Compensationamount n/aGautam Patel↗
- May 7, 26Compensationamount n/aJeffrey P. George↗
- May 7, 26Compensationamount n/aDeborah M. Autor↗
- May 7, 26Compensationamount n/aJ KEVIN BUCHI↗
- Mar 4, 26Compensationamount n/aNikita ShahExecutive Vice President↗
- Mar 4, 26Tax$239KNikita ShahExecutive Vice President↗
- Mar 4, 26Compensationamount n/aANDREW S BOYERExecutive Vice President↗
- Mar 4, 26Tax$255KANDREW S BOYERExecutive Vice President↗
- Mar 4, 26Compensationamount n/aTasos KonidarisExecutive Vice President & CFO↗
- Mar 4, 26Tax$293KTasos KonidarisExecutive Vice President & CFO↗
- Mar 4, 26Compensationamount n/aJason B. DalyEVP, Chief Legal Officer↗
- Mar 4, 26Tax$207KJason B. DalyEVP, Chief Legal Officer↗
- Mar 4, 26Compensationamount n/aChirag K. PatelPresident & Co-CEO↗
- Mar 4, 26Tax$503KChirag K. PatelPresident & Co-CEO↗
- Mar 4, 26Compensationamount n/aChintu PatelCo-CEO↗
- Mar 4, 26Tax$385KChintu PatelCo-CEO↗
- Mar 3, 26Compensationamount n/aNikita ShahExecutive Vice President↗
- Mar 3, 26Tax$246KNikita ShahExecutive Vice President↗
- Mar 3, 26Compensationamount n/aNikita ShahExecutive Vice President↗
- Mar 3, 26Tax$306KNikita ShahExecutive Vice President↗
- Mar 3, 26Compensationamount n/aNikita ShahExecutive Vice President↗
The full record holds 253 transactions and goes back to Dec 1, 21.
Its sector and its market
Amneal Pharmaceuticals Inc. among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Amneal Pharmaceuticals Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Amneal Pharmaceuticals Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- 250 clean closes in the period.
- SEC records
- 672 documents on file, from Nov 21, 2017 to Sep 21, 2026.
- Company description
- Wikipedia, read on Sep 3, 2026.
- This page
- Generated on Oct 18, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.